FDAAdvisoryCommittee.com
March 1, 2010 - Cardiovascular and Renal Drugs Advisory Committee
BLA - belatacept injectable (Bristol Myers Squibb)
Agenda: On March 1, 2010, the committee will discuss biologics license application (BLA) 125288, for belatacept injectable, by Bristol Myers Squibb, to be used in patients with kidney transplants to prevent rejection of the transplanted kidney.
Please Click HERE for our current calendar of upcoming events
To sign up for the live webcast, go to http://fdaac.com
FDAAdvisoryCommittee.com
No comments:
Post a Comment